n recent years the role of neuropeptides in the central regulation of arterial pressure and the pathogenesis of hypertension has been the subject of considerable attention. Of all the neuropeptides, vasopressin (AVP) has been one of the most widely studied. The availability of sophisticated immunocytochemical and biochemical methods has permitted localization of AVP in areas of the brain known to be involved in cardiovascular regulation. In addition, specific AVP receptors with high affinity have been found in these brain areas.
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n recent years the role of neuropeptides in the central regulation of arterial pressure and the pathogenesis of hypertension has been the subject of considerable attention. Of all the neuropeptides, vasopressin (AVP) has been one of the most widely studied. The availability of sophisticated immunocytochemical and biochemical methods has permitted localization of AVP in areas of the brain known to be involved in cardiovascular regulation. In addition, specific AVP receptors with high affinity have been found in these brain areas.
Several lines of evidence suggest that central AVP plays a role in the control of blood pressure and heart rate in both normotensive and hypertensive animals. Administration of AVP into the central nervous system produces changes in arterial pressure and heart rate that can be reversed by competitive antagonists. AVP interacts with neurotransmitters such as catecholamines, which are involved in arterial pressure regulation. It is also a potent releasing factor for adrenocorticotropic hormone (ACTH)-corticosterone, which in turn acts on the cardiovascular system. Agents that inhibit the interaction of AVP with its receptors have cardiovascular effects. Furthermore, levels of AVP and its receptor are altered in hypertensive states. Finally, increased sensitivity to the pressor effects of AVP has been described in experimental models of hypertension.
This review will focus on evidence for a central role for AVP in cardiovascular regulation and the pathogenesis of hypertension, and discussion will mainly focus on work done in rats. It should be noted that there is increasing evidence for species differences in responsiveness to AVP and mechanisms of action of AVP. For a more detailed discussion of the neuroanatomy, biochemistry, molecular biology, and physiology of this peptide, AVP, together with its precursor neurophysin, is synthesized in the magnocellular neurons of the supraoptic (SON), paraventricular (PVN), and suprachiasmatic (SCN) nuclei of the hypothalamus. Neurophysin and AVP are produced as part of a single precursor molecule, packaged into neurosecretory granules, and transported axonally to nerve endings located in the neurohypophysis where they are stored and secreted into the systemic circulation. Numerous anatomic studies have demonstrated that the hypothalamic AVP synthesizing nuclei send AVP-containing fibers to a number of central neural target areas in addition to the neurohypophysis. AVP-containing fibers and terminals have been observed in the entire neuroaxis from the olfactory bulb to the caudal end of the spinal cord. 67 As can be seen from Figure 1 and Table 1 , a number of areas innervated by AVP-containing fibers are involved in cardiovascular regulation. These include the locus coeruleus, nucleus tractus solitarius (NTS), dorsal motor nucleus of the vagus, anterior ventral region of the third cerebral ventricle (AV3V region), central gray, and the intermediolateral column of the spinal cord. 6714 - 16 The highest density of vasopressinergic fibers is in the NTS and dorsal motor nucleus of the vagus, whereas only scattered fibers are present in the cerebral cortex. Because AVP-containing projections make axosomatic and axodendritic contacts with these target areas, AVP may modulate the activity of neuronal pathways involved in blood pressure regulation. 7 Immunohistochemistry at the electron microscopic level has demonstrated that these contacts have the characteristics of true synapses. 17 In addition, AVP has been identified in synaptosomes of extrahypothalamic nerve terminals, 18 and there is evidence for synaptic release of AVP in extrahypothalamic target areas. and causes an accumulation of secretory products. These include the bed nucleus of the stria terminalis, dorsal medial hypothalamus, medial amygdala, and locus coeruleus. 21 Quantitative measurements of AVP/neurophysin in discrete regions of the brain and spinal cord by radioimmunoassay generally support the findings from immunohistochemical studies. 22 AVP has also been demonstrated in the cerebrospinal fluid (CSF), 2324 suggesting that it is found in neurons or fibers located near the ventricular system. The physiological stimuli that release AVP into the CSF are poorly understood. Dehydration causes release of AVP into the plasma but does not change CSF levels of AVP. In contrast, hemorrhage and electrical stimulation of the hypothalamus cause a release of AVP into the CSF as well as the plasma. 24 There is a pronounced diurnal rhythm of AVP in CSF, and much of the peptide cleared from the CSF reaches the bloodstream in a biologically active form. The physiological function of AVP in the CSF is not known, but there has been evidence that suggests it may be involved in intracranial pressure control. 25 In addition to synaptic release of AVP, several papers have reported actions of this peptide on neuronal firing rate in several brain regions. 26 
"
28 Localization of AVP in areas of the brain that control sympathetic outflow and baroreceptor reflex activity, demonstration of synaptic release of AVP, and the finding that this peptide has an action on neuronal firing rate in several brain regions, together with the observation of AVP binding in the same regions, 29   " 31 strongly suggest that AVP may act as a neurotransmitter in these regions.
The PVN and SON not only innervate areas of the brain known to be involved in cardiovascular regulation, but they receive afferent projections from cardiovascular centers. 33 These nuclei contain catecholaminergic terminals derived from the Al (noradrenergic) and Cl (adrenergic) cell groups of the ventrolateral medulla, the A2, Cl, and C3 cell groups of the dorsal medial medulla, and the A6 cell group of the locus coeruleus ( Figure 2 ). Work of Cunningham and Sawchenko, 33 using a method for tract tracing coupled with immunocytochemical staining, has provided new information on the organization, distribution, and morphology of noradrenergic inputs to the PVN and SON. The Al group of the ventrolateral medulla provides projections that end preferentially in aspects of the magnocellular division of the PVN and SON in which vasopressinergic neurons are clustered. Only minor and variable inputs to the parvocellular regions of the PVN were evident. The Al group receives afferent input from the NTS. Through these connections, information from atrial stretch receptors, arterial baroreceptors, and chemoreceptors is conveyed to the magnocellular AVP neurons. Projections from the A2 region (localized to a relatively discrete aspect of the medial part of the NTS) were found to be preferentially directed to the parvocellular division of the PVN. In addition, a less dense projection to the magnocellular division of the PVN and SON was consistently found. Cell groups from the A2 region, however, displayed no distinctive topography with respect to oxytocinergic versus vasopressinergic regions of these nuclei. Similarly, projections from the A6 region of the locus coeruleus were confined to the periventricular parvocellular portion of the PVN. Discrete retrograde tracer deposits in the SON failed to label neurons in the locus coeruleus. 33 This finding and those above are consistent with the notion that the locus coeruleus provides no substantial direct innervation of magnocellular neurosecretory neurons. Other afferent connections to the hypothalamic vasopressin synthetic nuclei are derived from the subfornical organ and median preoptic area. Fibers from the arcuate nucleus region, which contain ACTH 1-39, dopamine, and acetylcholine, project to the parvocellular regions of the PVN. The preoptic region and various hypothalamic nuclei, parabrachial nucleus, locus coeruleus, and NTS send projections to the parvocellular regions of the PVN. The preoptic region and various hypothalamic nuclei, parabrachial nucleus, locus coeruleus, and NTS send projections to the parvocellular neurons of the PVN, which in turn are connected to the magnocellular neurons of this nucleus. By virtue of its connection to the neural lobe, median eminence, and autonomic centers in the brain stem (i.e., locus coeruleus, dorsal motor nucleus of the vagus, parabrachial nucleus, and NTS) and spinal cord, the PVN may be a central area involved in the integration of endocrine and autonomic responses and the regulation of the cardiovascular system. 79 In addition, studies of Ciriello and colleagues 34 - 35 have shown that lesions of PVN attenuate the development of hypertension in SHR 34 and lower blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
35

Central Cardiovascular Effects of Vasopressin
AVP and vasotocin have been demonstrated in extrahypothalamic brain regions in all classes of vertebrates from the most primitive (Agnathans) to mammals, including humans. 10 - 3637 The finding that AVP or AVP-related peptides are maintained throughout evolution supports the hypothesis that this peptide has physiological significance. Moreover, the diverse origin and widespread distribution of AVP-containing fibers suggest that AVP is involved in the regulation of a variety of central neural functions. Several studies have been carried out to determine whether release of AVP into the circula-tion is coupled to release of this peptide in extrahypothalamic areas. These studies have given evidence that each of the sites in which AVP is produced is influenced by different stimuli, 49 and locus coeruleus, 50 produce long lasting increases in blood pressure and heart rate. The cardiovascular responses of AVP are due to a central effect and not due to leakage of the peptide into the periphery as they are blocked by central but not peripheral administration of specific AVP receptor antagonists. 40 - 41 ' 44 ' 49 ' 50 The cardiovascular responses to central administration of AVP appear to be mainiy due to stimulation of sympathetic vasomotor activity, as they are significantly attenuated by ganglionic blocking agents, a-adrenergic and 0-adrenergic receptor antagonists.
-
44
- 47 These studies have led to the hypothesis that AVP may be involved in regulation of sympathetic outflow.
Further evidence for this hypothesis has come from studies on the direct action of AVP on components of the sympathetic nervous system. AVP, acting on V, receptors, was found to excite lateral horn cells, which contain a number of preganglionic sympathetic neurons, in in vitro slices of neonatal rat spinal cord. This excitatory effect came about by direct depolarization and an indirect effect via the release of excitatory transmitters. 51 This depolarizing action of AVP on lateral horn cells is in agreement with studies in cats showing that electrical stimulation of neurons in the PVN increased sympathetic outflow, 52 and iontophoresis of AVP onto single sympathetic preganglionic neurons in the intermediolateral nucleus of the spinal cord increased the firing rate of these neurons. 53 In a recent study, using an in vitro slice preparation from the rostroventrolateral medullary reticular nucleus, it was found that AVP produced dose-dependent excitation of the pacemaker neurons. 26 These pacemaker cells are believed to be a source of tonic excitatory drive to sympathetic vasomotor preganglionic neurons, and the basal discharge of the cells can be upregulated or downregulated by a number of neuroregulatory peptides. The reports of AVP immunoreactive fibers and terminals in the rostroventrolateral medulla, 54 the presence of specific V, receptors on pacemaker neurons, and the finding of an excitatory effect of AVP on the discharge rate of these neurons 26 suggest that central AVP may alter arterial pressure via an effect on these neurons.
AVP may also influence sympathetic outflow via the locus coeruleus. This region receives vasopressinergic innervation, 54 and microinjection of AVP into this nucleus produces an increase in arterial pressure and heart rate, which is mediated by AVP receptors and increased sympathetic outflow. 50 Microiontophoresis of AVP in the locus coeruleus increases the discharge rate of neurons in this area. 28 Bilateral electrolytic lesions of the locus coeruleus attenuate the pressor and abolish the tachycardiac response to intracerebroventricular AVP. 55 Taken together, these findings suggest that AVP may also act on the locus coeruleus to increase sympathetic outflow.
There is increasing evidence that AVP and the baroreceptor reflex are intricately linked. Neuroanatomic studies have shown that hypothalamic AVPsynthesizing nuclei receive neural projections from the region of the NTS and, in turn, send projections to cardiovascular centers in the medulla, NTS, and spinal cord. 67 Functional studies have shown that the baroreceptor reflex is involved in regulation of AVP secretion, 56 -57 with decreased baroreceptor activity producing an increase 58 and enhanced baroreceptor activity producing a decrease in AVP release. 59 Accordingly, excitation of the baroreceptor reflex has been found to produce a decrease in single unit activity in the PVN and SON, whereas a decrease in baroreceptor reflex activity produced an increase in single unit activity. 60 The effect of AVP or AVP-containing neurons on baroreceptor function is less certain. There are differences between the effects of peripheral and central AVP on baroreceptor reflex function. Moreover, recent studies have identified important species differences in the effect of AVP on baroreceptor reflex function. The initial study, suggesting an effect of AVP on the baroreceptor reflex, came from Cowley et al 61 and showed that the pressor response to AVP was augmented more than norepinephrine in baroreceptor-denervated dogs. This work was confirmed by Montani et al 62 in conscious dogs and extended by Liard et al, 63 who demonstrated that AVP given into the vertebral artery produced pronounced bradycardia and vasodilation, whereas a similar dose given intravenously had little effect. Taken together, these data suggest that AVP enhances the inhibitory effect of the arterial baroreceptor reflexes on heart rate and sympathetic outflow and does this by a central mechanism of action. Studies in rabbits confirmed the findings in dogs and, in addition, showed that the area postrema was critical for AVP-induced augmentation of baroreceptor reflex inhibition of peripheral sympathetic nerves. 6466 Imaizumi and Thames 67 showed that AVP in the CSF, unlike that in the plasma, failed to alter sympathetic activity during increases in carotid artery pressure, but it did facilitate reflex increases in sympathetic activity during carotid hypotension. Hence, the actions of AVP in the plasma and cerebrospinal fluid appear to differ. In contrast to studies in rabbits and dogs, work done in rats and cats have shown that central AVP may exert an inhibitory influence on baroreceptor reflex function. 69 rats suggesting an inhibitory action of AVP on neurons of the NTS. Most studies in the NTS have been performed using nanogram quantities of AVP. In a recent study, Brattstrom et al 70 observed that microinjections of picogram quantities of AVP into the NTS produced a dose-dependent decrease in blood pressure and heart rate. Whether this discrepancy is due to a true dose-responserelated phenomenon or to differences in anesthetic used or experimental protocol remains to be tested. Brattstrom et al 70 observed that the effects of picogram amounts of AVP took several minutes to develop. This suggests that AVP may be stimulating the release of or interacting with another transmitter such as glutamate, norepinephrine, or /3-endorphin, which are present in the NTS and have been shown to decrease blood pressure and heart rate when injected into the NTS. Studies of Unger et al 68 have demonstrated that intracerebroventricular injection of subpressor doses of AVP produced an attenuation in baroreceptor reflex control of heart rate, whereas injection of a Vj AVP receptor antagonist at a dose that had no intrinsic action on the cardiovascular system produced an increase in the sensitivity of baroreceptor reflex control of heart rate. These results suggest that neuronal AVP can decrease the sensitivity of the baroreceptor reflex by acting on V, AVP receptors in the brain.
Studies assessing baroreceptor reflex activity and the effect of exogenous AVP on baroreceptor reflex function in Brattleboro rats homozygous for diabetes insipidus (DI), which are unable to synthesize AVP, have presented equivocal results. Three different laboratories have presented evidence that DI rats show an increase, 55 a decrease, 71 or no difference 72 in baroreceptor reflex sensitivity in comparison with their controls, the Long-Evans rat. The reason for these discrepancies is not known; however, it may rest with differences among the various colonies of DI rats.
Although it was not the goal of this report to discuss the other neurohypophyseal hormone oxytocin, it should be mentioned that there is increasing evidence that this peptide may also play a role in cardiovascular regulation. Systemic administration of this peptide produced a decrease in blood pressure and cardiac output. 73 Oxytocin was found to reduce pressor responses to mesencephalic stimulation 74 and norepinephrine 75 and, when injected into the dorsal motor nucleus of the vagus, produced bradycardia via activation of neurons in this region. 76 Furthermore, there appears to be an interaction between oxytocin and the baroreceptor reflex as sinoaortic denervation increased both basal release and osmotically induced release of oxytocin. 77 
Vasopressin Receptors
The actions of AVP are mediated by membranebound receptors of two subtypes. 78 The V! receptor mediates the vasoconstrictor and hepatic glycogenolytic actions of AVP via phosphatidyl inositol hydrolysis. The V 2 receptor mediates the antidiuretic effect of AVP on renal collecting ducts via adenylate cyclase. The AVP receptor in the central nervous system is most similar to the V[ receptor. However, the anterior pituitary AVP receptor involved in vasopressin-induced corticotropin release differs from the vascular, hepatic, and brain Vi receptor and has been designated as a V lb receptor. Several studies using tritiated AVP ([ 3 H]AVP), 79 tritiated V r selective ligands, 80 and a radioiodinated (iodine-125) specific V, receptor antagonist 81 have localized AVP receptors in the brain using quantitative autoradiography. Results of these studies using the different ligands have not been consistent. Previous studies of autoradiographic localization of AVP in brain using Interestingly, AVP receptors have not yet been identified in some areas of the brain receiving AVP innervation, such as the subfornical organ, organum vasculosum of the lamina terminalis, and locus coeruleus. The lack of AVP receptors in these areas is perplexing as they are densely innervated with AVPcontaining fibers. In addition, microinjection or microiontophoresis of AVP into the locus coeruleus produces immediate increases in arterial pressure and neuronal activity, respectively. These effects are
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blocked by pretreatment with a selective V, AVP antagonist. The reason for the discrepancies between receptor binding and immunocytochemical and functional studies is not known but may relate to the properties of the ligand and its affinity for the V! and other peptide receptors, multiple receptor subtypes, and cross-reacting antibodies in immunocytochemical studies.
Factors that modulate AVP receptors are poorly understood. Further, there have been few studies on changes in AVP receptor binding in hypertension. The renal V 2 receptor has been reported to undergo desensitization in response to acute elevations in AVP, 82 but little is known about AVP modulation of the V, receptor. In DI rats, V, binding site concentration in the liver and septum has been shown to be greater than in Long-Evans control rats, whereas the V 2 [ 3 H]AVP binding site concentration has been shown to be similar in both strains. 82 In recent studies by Shewey 86 reported that dexamethasoneinduced hypertension in rats was associated with enhanced responses of mesenteric arteries to AVP but not to norepinephrine or angiotensin II, suggesting increased sensitivity or number of AVP binding sites. The effect of steroids on AVP binding is not known with certainty, but adrenalectomy decreased AVP binding in the pituitary (V lb ), an effect that was inhibited by corticosterone. Adrenal steroids exert a dual action on AVP-sensitive adenylate cyclase in the kidney increasing the number of binding sites and increasing the efficiency of receptor-enzyme coupling. 87 Our laboratory has recently reported that DOCA treatment of rats increased the number of AVP receptors in the hypothalamus. 88 It has also recently been reported that the number of renal AVP receptors (V 2 ) is also increased in DOCA-treated rats. 89 To date, purification of either the Vj or V 2 receptor subtype to homogeneity has not been accomplished. 82 This has been due, in part, to lack of suitable affinity ligands, which covalently label the receptor, relatively low abundance of receptor in AVP-responsive tissues, and difficulty in solubilizing the receptor in a form that binds AVP.
The cellular and molecular mechanisms of action of AVP are not well understood. To gain an understanding of how the binding of AVP to its specific receptor mediates a precise biochemical effect and how the AVP receptor is regulated, the AVP receptor or AVP receptor subtypes from various tissues (i.e., brain, vascular tissue, kidney) will have to be cloned, expressed, and characterized. The molecular cloning and expression of the AVP receptor will greatly facilitate the biochemical characterization of this receptor and improve our understanding of the mechanism of action of AVP in normal cardiovascular regulation and in hypertension.
Central Vasopressin in Hypertension
The role of AVP in the pathogenesis of hypertension has been controversial. Although plasma levels of AVP have been reported to be increased in many models of hypertension, it has not been possible to demonstrate that chronic administration of AVP, at levels similar to that seen in hypertension, can sustain an elevated arterial pressure by either vasoconstriction or expansion of plasma volume or even total body fluid volume. Furthermore, it has not been possible to consistently demonstrate that administration of pressor antagonists of AVP cause more than a transient fall in blood pressure in any model of experimental hypertension. 90 Thus, it is unlikely that AVP plays a pathogenic role in hypertension through its peripheral vasoconstrictor or antidiuretic effects. Nevertheless, numerous studies have suggested a potential central role for AVP in hypertension. It has been postulated that AVP plays a role in hypertension through its ability to increase sympathetic outflow. Sympathetic overactivity has been established for most models of hypertension. 91 In genetic models of hypertension, inborn hyperactrvity of the AVP system may lead to central and peripheral sympathetic hyperactivity. In acquired models of hypertension, AVP may serve as the factor linking salt and DOCA-salt to the sympathetic nervous system. 91 
Deaxycorticosterone Acetate-Salt Hypertension
The DOCA-salt model of hypertension has been one of the most extensively studied, and there is strong evidence in this model for a possible central role of AVP in hypertension. Destruction of central adrenergic structures with 6-hydroxydopamine (6-OHDA) 92 or electrolytic lesion of selective areas of the brain 93 in rats before treatment with DOCA and salt prevents the development of hypertension. These findings have led to the hypothesis that there is a centrally located "trigger" mechanism for the initiation of DOCA-salt hypertension. It has been speculated that this central mechanism participates in the development of hypertension by increasing peripheral sympathetic outflow. 94 Recent studies suggest that AVP is a strong candidate for participation in the centrally located trigger mechanism. 95 " 98 A primary role for AVP in the pathogenesis of DOCA-salt hypertension was first suggested by Friedman et al, 95 who found that surgical ablation of the median eminence prevented the development of DOCA-salt hypertension, whereas administration of large doses of the peptide hastened its onset. Subsequently, elevations in plasma and urinary AVP levels were reported in DOCA-salt-treated rats in both early and chronic stages of hypertension.
96
- 97 Administration of an AVP antagonist or antiserum directed against AVP produced an acute reduction in arterial pressure in DOCA-salt hypertensive rats.
- 97 Moreover, hypertension failed to develop in DI rats when treated with DOCA-salt but did develop when replaced with the AVP. 9899 Although evidence strongly suggests participation of AVP in DOCA-salt hypertension, its mechanism of action is unclear. DOCA-salt-treated rats showed significantly greater increases in mean arterial pressure and heart rate in response to intracerebroventricular administration of AVP than did control rats. Moreover, a more than 10-fold lower threshold dose of AVP was required to produce cardiovascular changes in DOCA rats (0.025 ng) compared with controls (2.5 ng). 40 Microinjection of AVP into the locus coeruleus produced increases in arterial pressure and heart rate due to stimulation of sympathetic outflow. 50 Moreover, microiontophoresis of AVP onto noradrenergic neurons of the locus coeruleus in DOCA-salt-treated rats produced a significantly greater increase in firing rate of these neurons than in control rats. 100 Increased sensitivity in response to locus coeruleus stimulation was seen not only in the established phase of DOCA-salt hypertension but also during the prehypertensive stage. and that the sensitivity and responsiveness of DOCAsalt hypertensive rats to centrally administered AVP were markedly increased 40 suggested that AVP might stimulate the sympathetic nervous system at a central level in this model. Further support for this hypothesis comes from studies in DI rats with or without lesion of the AV3V, 101 an area that receives vasopressinergic innervation. 7 Supplementation of AVP restored the capacity of DI rats to develop DOCAsalt hypertension but not rats with AV3V lesions, although plasma levels of AVP were similar in sham and lesioned rats and comparable with normal, intact rats treated with DOCA-salt. In addition, lesions in the area postrema 102 or the locus coeruleus, 103 areas also receiving vasopressinergic innervation, prevented or attenuated the development of DOCA-salt hypertension. Taken together, these results suggest a link between AVP and the sympathetic nervous system in DOCA-salt hypertension. AVP may play a role in hypertension by a direct action via vasopressinergic innervation on central neural centers controlling sympathetic outflow. A hallmark of hypertension is a resetting or alteration of the arterial baroreceptor reflex. Rapid downward resetting can occur when blood pressure is decreased to normal, suggesting that resetting is not due exclusively to structural abnormalities in the arterial receptors themselves. 104 - 105 The findings that central administration of vasopressin 40 -41 and increased activity of the PVN and SON attenuate baroreceptor reflex activity 52 suggest that alterations in the function of these nuclei or AVP may participate in the resetting of the baroreceptor reflex in hypertension. In addition, AVP may stimulate sympathetic outflow in DOCA-salt hypertension by resetting the baroreceptor reflex.
Genetic Hypertension
Genetic models of hypertension such as the spontaneously hypertensive rat (SHR), the Dahl saltsensitive rat, and the Sabra rat are characterized by increased sympathetic activity or alterations in brain catecholamines.
106
- 108 There are conflicting reports concerning the role for AVP in genetic hypertension. There are reports in the literature of high central and peripheral levels of AVP and increased AVP gene expression in SON and PVN in these rats at various ages as well as a fall in blood pressure in response to administration of AVP antagonists. 109 
"
112 There are also reports in the literature showing opposite effects (e.g., low central and peripheral levels of AVP and lack of a fall in blood pressure in response to AVP antagonists 113 " 115 ). Studies with administration of antagonists showing lack of effect on blood pressure are difficult to interpret and do not necessarily present conclusive evidence against a role for central AVP in hypertension. Central AVP may be contributing to hypertension at an earlier age than when the treatment is usually begun (less than 4 weeks). Alterations in AVP content have been reported in primary neuronal cultures from brains of 1-day-old SHR and Wistar-Kyoto (WKY) rat pups. In addition, SHR show abnormalities in the distribution of central catecholaminergic and vasopressinergic neurons in comparison with normotensive rats. 116 DI rats have also shown abnormalities (fewer fluorescent varicosities) in noradrenergic innervation of hypothalamic nuclei. 117 Taken together, these studies suggest that AVP may be essential for normal catecholaminergic innervation of the brain and that an increase in AVP activity in fetal or newborn SHR might alter the pattern and density of catecholaminergic innervation and underlie the increase in sympathetic activity that characterizes this hypertensive model.
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Another factor that must be considered with use of peripheral AVP antagonists is that they may not penetrate the blood-brain barrier and reach sites in the central nervous system that are relevant to regulation of blood pressure. The studies with intracerebroventricular injection of AVP suggest that peripheral AVP antagonism does not block the response to central administration of AVP.
4041 Additional opposition to the hypothesis that AVP plays a role in genetic hypertension is the study of Lang et al 117 who crossbred DI rats with SHR of the stroke-prone substrain (SHRSP). Lang et al U7 found that hypertension still developed in these AVP-deficient SHRSP-DI rats. However, results from studies in these rats may not present conclusive evidence against a role for AVP in the development of hypertension in SHR that are not stroke-prone. SHRSP have not shown alterations in AVP that are similar to SHR not prone to strokes. In addition, DI rats show pronounced changes in other hormones, namely, increases in the renin-angiotensin II system and a pronounced activation of oxytocin, which might participate in maintaining hypertension in this strain in place of AVP. 111 In conclusion, there is strong evidence for a central role for AVP in normal cardiovascular regulation and in the pathogenesis of hypertension. Central administration of AVP produces cardiovascular responses attributable to stimulation of sympathetic outflow. Because most models of hypertension have been characterized by hyperactivity of the sympathetic nervous system, AVP may, in early stages of hypertension, alter sympathetic outflow via an effect on central neural structures controlling the sympathetic nervous system. Central administration of AVP also produces an increase in heart rate; thus, the peptide appears to override the ability of the baroreceptor reflex to buffer changes in arterial pressure. Hence, AVP may participate in baroreceptor reflex resetting in hypertension and alter sympathetic outflow via effects on the baroreceptor reflex. 
